Replimune (REPL) study of RP1 in combination with cemiplimab

Replimune (REPL) study of RP1 in combination with cemiplimab did not meet either of the two primary endpoints

Replimune (REPL) study of RP1 in combination with cemiplimab did not meet either of the two primary endpoints

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

, Philip Astley Sparke , Inquiriesarleen Goldenbergreplimune , Inquirieschris Brinzeyicr Westwicke , International Congress , Exchange Commission , Securities Exchange , Replimune Group Inc , Nasdaq , Regeneron Pharmaceuticals , Replimunereplimune Group Inc , Drug Administration , Replimune Group , Master Clinical Trial Collaboration , Supply Agreement , Initial Data , All Patients , Data Snapshot , Melanoma Research , Call Detailsreplimune , Replimunereplimune Group , Looking Statementsthis , Securities Act , Securities Exchange Act , Annual Reports , Quarterly Reports ,